Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma
Anticancer Research · 2024
DOI: 10.21873/anticanres.16897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Kodcharat Cheevapruk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 10-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Multiple myeloma (MM), the second most common hematological malignancy, is characterized by the accumulation of malignant plasma cells within the bone marrow. Despite various drug classes for MM treatment, it remains incurable, necessitating novel and efficacious agents. This study aims to explore the anti-cancer activity of a midkine inhibitor, iMDK (C21H13FN2O2S), in myeloma cell lines. MATERIALS AND METHODS: This study assessed the antiproliferative activity using the MTT assay. Cell cycle and apoptosis were evaluated using flow cytometry. To further investigate the inhibitory mechanism, western blotting was used to detect cell cycle-related proteins, pro-apoptotic proteins, and anti-apoptotic proteins. RESULTS: iMDK inhibits MM cell proliferation in a dose- and time-dependent manner, inducing cell cycle arrest and apoptosis. The reduction in Cdc20 expression by iMDK treatment leads to G2/M phase cell cycle arrest. Furthermore, iMDK down-regulates anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, and c-FLIP), thereby activating both intrinsic and extrinsic apoptosis pathways. CONCLUSION: iMDK could be a potential candidate for MM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
- Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Graduate School of Fisheries and Environmental Studies, Nagasaki University, Nagasaki, Japan.
- Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; okadas@kumamoto-u.ac.jp.
Zitieren
APA
Cheevapruk, K., Ueno, M., Sungwan, P., Sittithumcharee, G., Kariya, R., Sampattavanich, S., & Okada, S. (2024). Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Anticancer Research. https://doi.org/10.21873/anticanres.16897
Vancouver
Cheevapruk K, Ueno M, Sungwan P, Sittithumcharee G, Kariya R, Sampattavanich S, et al. Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Anticancer Research. 2024. doi:10.21873/anticanres.16897
BibTeX
@article{Cheevapruk2024,
author = {Cheevapruk, Kodcharat and Ueno, Mikinori and Sungwan, Prin and Sittithumcharee, Gunya and Kariya, Ryusho and Sampattavanich, Somponnat and Okada, Seiji},
title = {Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16897}
}
EUVIMED